Overview

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Status:
Completed

Trial end date:
2018-04-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to show bioequivalence of test product to reference product based on baseline-adjusted forced expiratory volume in one second (FEV1).

Phase:

Phase 3

Details

Lead Sponsor:

Lupin, Inc.

Treatments:

Bromides
Tiotropium Bromide